Stocksigma LogoStocksigma Logo

Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio to Advance ADC Strategy

Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) strategy, expecting completion by Sep'26

Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio to Advance ADC Strategy

Cohance Lifesciences Ltd 路 Press Release 路 04 Sept 2026, 1:40 am

Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio to Advance ADC Strategy Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) strategy, expecting completion by Sep'26. A $13M allocation increases Cohance's equity in NJ Bio from 56.0% to 67.3%, integrating NJ Bio's CRDMO services with Cohance's commercial manufacturing. The remaining $5M secures a controlling 65% stake in Aruka Bio, making the preclinical ADC developer a direct subsidiary. This reorganization distinctly separates NJ Bio's customer-facing commercial operations from Aruka's proprietary drug pipeline development, positioning Aruka for future licensing partnerships.

Original exchange filing (PDF)

More announcements from Cohance Lifesciences Ltd

All Cohance Lifesciences Ltd announcements